Abstract
Background: COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection.
Methods: Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15th June 2021.
Results: There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (n = 493) and VIP (n = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (n = 501, 55.2%), most women were vaccinated in their second or third trimester (n = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (n = 577, 63.5%).
Conclusion: Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.
| Original language | English |
|---|---|
| Article number | ARTN 1753495X221076713 |
| Pages (from-to) | 40-47 |
| Number of pages | 8 |
| Journal | Obstetric Medicine |
| Volume | 16 |
| Issue number | 1 |
| Early online date | 8 Feb 2022 |
| DOIs | |
| Publication status | E-pub ahead of print - 8 Feb 2022 |
Bibliographical note
Funding Information: No funding information.Open Access: No Open Access licence.
Publisher Copyright: Copyright © 2022 by SAGE Publications
Citation: Richardson JL, Stephens S, Chappell LC, et al. Monitoring the safety of COVID-19 vaccination in pregnancy in the UK: A national study using the UK Obstetric Surveillance System (UKOSS), UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems. Obstetric Medicine. February 2022.
DOI: 10.1177/1753495X221076713
Keywords
- COVID-19 vaccine
- SARS-coV-2
- obstetric surveillance
- pharmacovigilance
- pregnancy
- teratology
- vaccination
